# Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis

> **NCT00179478** · PHASE4 · COMPLETED · sponsor: **Beth Israel Deaconess Medical Center** · enrollment: 155 (actual)

## Conditions studied

- Multiple Sclerosis
- Optic Neuritis
- Transverse Myelitis
- Acute Brainstem/Cerebellar Syndrome

## Interventions

- **DRUG:** interferon beta 1a 30 ug IM once weekly

## Key facts

- **NCT ID:** NCT00179478
- **Lead sponsor:** Beth Israel Deaconess Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-02
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 155 (ACTUAL)
- **Last updated:** 2017-09-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00179478

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00179478, "Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00179478. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*